RECURRENT MALIGNANT SOLID NEOPLASM
Clinical trials for RECURRENT MALIGNANT SOLID NEOPLASM explained in plain language.
Never miss a new study
Get alerted when new RECURRENT MALIGNANT SOLID NEOPLASM trials appear
Sign up with your email to follow new studies for RECURRENT MALIGNANT SOLID NEOPLASM, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo shows promise in early cancer trial
Disease control CompletedThis early-phase trial tested a combination of two drugs, sapanisertib and ziv-aflibercept, in 83 adults with advanced solid tumors that had spread or could not be removed by surgery. The main goal was to find the safest dose and identify side effects. The approach aims to slow t…
Matched conditions: RECURRENT MALIGNANT SOLID NEOPLASM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 04:12 UTC
-
New drug shows promise for kids with Hard-to-Treat cancers
Disease control CompletedThis study tested a drug called samotolisib in 18 children and teens whose cancers had spread, come back, or stopped responding to treatment. The drug works by blocking certain enzymes that cancer cells need to grow. The goal was to see if the drug could shrink or stop the cancer…
Matched conditions: RECURRENT MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
New hope for kids with tough cancers: targeted pill shows promise
Disease control CompletedThis study tested a drug called tazemetostat in 20 children whose cancers had come back or weren't responding to treatment. The children had specific gene changes (EZH2 or SWI/SNF) in their tumors. The goal was to see if the drug could shrink or control the cancer. This is a dise…
Matched conditions: RECURRENT MALIGNANT SOLID NEOPLASM
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 13, 2026 16:01 UTC